Evidence map›Paper›PMID 27286837›Full record

ReviewDer Internist2016

[Hyperuricemia and gout : New aspects of an old disease].

M Witt, H Schulze-Koops

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Internist, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

M WittRheumazentrum Bad Aibling-Erding, Gestütring 19, 85435, Erding, Deutschland. witt@rz-bae.de.
H Schulze-KoopsRheumaeinheit, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, München, Deutschland.
LMU Klinikum · DESchön Klinik Bad Aibling · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gouty arthritis is one of the most common arthritides. Due to increasing life expectancy and changing life style, a rising incidence and prevalence of gout can be expected. Because of associations with the diseases metabolic syndrome and cardiovascular morbidity, gout patients often suffer from significant morbidity. Besides the consequent usage of conventional therapeutics, new treatments for gout attacks and for lowering urate levels are available even for patients refractory to conventional therapy.

Indexed as

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntirheumatic AgentsArthritis, GoutyDiagnosis, DifferentialEvidence-Based MedicineGout SuppressantsHumansHyperuricemiaRadiography, Dual-Energy Scanned ProjectionThioglycolatesTreatment OutcomeTriazolesUricosuric AgentsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntirheumatic AgentscanakinumabGout SuppressantslesinuradThioglycolatesTriazolesUricosuric AgentsAnakinraCanakinumabComputed X ray tomography, dual energyEpidemiology, goutLesinurad

Identifiers

PMID27286837
OpenAlexW2439759531

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.